Citations

Showing 10 of 108152 citations.

Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial
Vermeire, Séverine , D’Haens, Geert , Baert, Filip , Kobayashi, Taku, Loftus, Edward V. , Bhatia, Siddharth , Agboton, Christian , Rosario, Maria , Chen, Chunlin , Zhang, Wenwen , Kisfalvi, Krisztina, Sandborn, William J. , Kobayashi, Taku , Loftus, Edward V , Kobayashi, Taku , Vermeire, Séverine , Danese, Silvio

Mayo Clinic

Journal of Crohn's and Colitis | August 16, 2021 | Volume: 16 | Issue: 1 | Pages: 27-38

10.1093/ecco-jcc/jjab133 | PMID 34402887 Get It

Abstract Background and Aims To report results from VISIBLE 2, a randomised, double-blind, placebo-controlled, phase 3 trial evaluating a new subcutaneous [SC] vedolizumab formulation as maintenance treatment in adults with moderately to severely active Crohn’s disease [CD]. Methods Following open-label vedolizumab 300 mg intravenous induction therapy at Weeks 0 and 2, Week 6 clinical responders (≥70-point decrease in CD Activity Index [CDAI] score from baseline) were randomised 2:1 to receive double-blind maintenance vedolizumab 108 mg SC or placebo every 2 weeks until Week 50. Assessments at Week 52 included clinical remission [primary endpoint; CDAI ≤150], enhanced clinical response [≥100-point decrease in CDAI from baseline], corticosteroid-free clinical remission among patients using a corticosteroid at baseline, clinical remission in anti-tumour necrosis factor [anti-TNF]-naïve patients, and safety. Results Following vedolizumab intravenous induction, 275 patients were randomised to vedolizumab SC and 135 to placebo maintenance. At Week 52, 48.0% of patients receiving vedolizumab SC versus 34.3% receiving placebo were in clinical remission [p = 0.008]. Enhanced clinical response at Week 52 was achieved by 52.0% versus 44.8% of patients receiving vedolizumab SC versus placebo, respectively [p = 0.167]. At Week 52, 45.3% and 18.2% of patients receiving vedolizumab SC and placebo, respectively, were in corticosteroid-free clinical remission, and 48.6% of anti-TNF-naïve patients receiving vedolizumab SC and 42.9% receiving placebo were in clinical remission. Injection site reaction was the only new safety finding observed for vedolizumab SC [2.9%]. Conclusions Vedolizumab SC is an effective and safe maintenance therapy in patients with CD who responded to two infusions of vedolizumab intravenous induction therapy.
Coronary Microvascular Dysfunction and the Risk of Atrial Fibrillation From an Artificial Intelligence-Enabled Electrocardiogram
Ahmad, Ali , Corban, Michel , Toya, Takumi , Attia, Zachi I. , Noseworthy, Peter A. , López-Jiménez, Francisco , Cohen, Michal Shelly, Sara, Jaskanwal Deep Singh , Ӧzcan, Ilke , Lerman, Lilach O. , Kapa, Suraj , Friedman, Paul A. , Sara, Jaskanwal D, Ozcan, Ilke, Noseworthy, Peter A , Kapa, Suraj , Lopez-Jimenez, Francisco , Toya, Takumi , Corban, Michel T , Attia, Zachi I , Ozcan, Ilke , Lerman, Amir

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | August 16, 2021 | Volume: 14 | Issue: 8 | Pages: No page available

10.1161/circep.121.009947 | PMID 34397262 Get It

Use of Artificial Intelligence Tools Across Different Clinical Settings
Siontis, Konstantinos C. , Arghami, Arman , Weston, Susan A., Attia, Zachi I. , Crestanello, Juan A. , Friedman, Paul A. , Chamberlain, Alanna M. , Gersh, Bernard J. , Arghami, Arman , Attia, Zachi I , Crestanello, Juan A , Chamberlain, Alanna M , Gersh, Bernard J , Noseworthy, Peter A.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | August 16, 2021 | Volume: 14 | Issue: 9 | Pages: No page available

10.1161/circoutcomes.121.008153 | PMID 34397260 Get It

Change in Rheologic Properties of Facial Soft-Tissue Fillers across the Physiologic Angular Frequency Spectrum
Hamade, Hassan, Bertucci, Vince , Fagien, Steven , Pavicic, Tatjana , Nikolis, Andreas , Lachman, Nirusha , Hadjab, Abdelbasste, Frank, Konstantin , Green, Jeremy B, Cotofana, Sebastian , Green, Jeremy B.

Mayo Clinic

Plastic & Reconstructive Surgery | August 16, 2021 | Volume: 148 | Issue: 2 | Pages: 320-331

10.1097/prs.0000000000008188 | PMID 34398083 Get It

Background: The number of soft-tissue filler injections performed in the United States is constantly increasing and reflects the high demand for enhanced facial and body attractiveness. The objective of the present study was to measure the viscoelastic properties of soft-tissue fillers when subjected to different testing frequencies. The range of tested frequencies represents clinically different facial areas with more [lips (high frequency)] or less [zygomatic arch (low frequency)] soft-tissue movement. Methods: A total of 35 randomly selected hyaluronic acid–based dermal filler products were tested in an independent laboratory for their values of G′, G″, tan δ, and G* at angular frequencies between 0.1 and 100 radian/second. Results: The results of the objective analyses revealed that the viscoelastic properties of all tested products changed between 0.1 and 100 radian/second angular frequency. Changes in G′ ranged from 48.5 to 3116 percent, representing an increase in their initial elastic modulus, whereas changes in G″ ranged from −53.3 percent (i.e., decrease in G″) to 7741 percent (i.e., increase in G″), indicating both an increase and a decrease in their fluidity, respectively. Conclusions: The increase in G′ would indicate the transition from a “softer” to a “harder” filler, and the observed decrease in G″ would indicate an increase in the filler’s “fluidity.” Changes in the frequency of applied shear forces such as those occurring in the medial versus the lateral face will influence the aesthetic outcome of soft-tissue filler injections.
Intraoperative Fracture of a Dual Modular Delta Ceramic Femoral Head During Total Hip Arthroplasty
Salmons, Harold I. , Ryan, Sean P. , Trousdale, Robert T. , Ryan, Sean

Mayo Clinic

JBJS Case Connector | August 16, 2021 | Volume: 11 | Issue: 3 | Pages: No page available

10.2106/jbjs.cc.21.00215 | PMID 34398843 Get It

Case: A 39-year-old man with cerebral palsy and hip dysplasia status post right Chiari osteotomy presented with right hip osteoarthritis in consultation for total hip arthroplasty (THA). During THA, a Delta ceramic head was misaligned on the taper, but this was obscured by an overlying dual modular polyethylene shell. When we attempted to tap the head onto the taper, fracture occurred requiring revision to a cobalt-chromium head due to slight taper damage. Conclusion: To our knowledge, this is the first reported case of intraoperative fracture of a BIOLOX Delta dual modular head.
Hot topics in interventional cardiology: Proceedings from the society for cardiovascular angiography and interventions (SCAI) 2021 think tank
Naidu, Srihari S. , Baron, Suzanne J. , Eng, Marvin H. , Sathanandam, Shyam , Zidar, David A., Feldman, Dmitriy N. , Ing, Frank F. , Latif, Faisal , Lim, Michael J. , Henry, Timothy D. , Dangas, George , Hermiller, James, Daggubati, Ramesh , Ang, Lawrence , Box, Lyndon C., Caputo, Ronald , Cohen, Mauricio G. , Coylewright, Megan , Duffy, Peter L. , Goldsweig, Andrew M. , Hagler, Donald J. , Hawkins, Beau M., Hijazi, Ziyad M. , Jayasuriya, Sasanka, Klein, Andrew , Kliger, Chad , Mahmud, Ehtisham , Messenger, John C. , Parikh, Sahil A. , Shishehbor, Mehdi H. , Yakubov, Steven J. , Alvarez‐Breckenridge, Jennifer, Baird, Colleen, Baker, David, Berry, Charles H., Bhattacharya, Manisha, Bilazarian, Seth, Bowen, Rosanne, Brounstein, Kevin, Cameron, Cole, Culbertson, Casey , Díaz, P, Emanuele, Susan, Evans, Erin, Fletcher, Rob, Fortune, Tina, Gaiha, Priya, Govender, Devi, Gutfinger, Dan , Haggstrom, Kurt, Herzog, Andrea, Hite, Denise, Kalich, Bethany , Kirkland, Ann, Kohler, Toni, Laurisden, Holly, Livolsi, Kevin, Lombardi, Lois, Marhenke, Kevin, Meikle, Joie, Moat, Neil, Popma, J.J., Rangwala, Novena , Simonton, Chuck, Stokes, J. W., Taber, Margaret , Tieché, Christopher, Venditto, John, Zinn, Laurie, Dangas, George , Daggubati, Ramesh , Shah, Binita , Ang, Lawrence , Cohen, Mauricio G , Goldsweig, Andrew M , Hagler, Donald J , Morray, Brian H , Parikh, Sahil A , Shishehbor, Mehdi H , Szerlip, Molly , Yakubov, Steven J , Grines, Cindy L , Baron, Suzanne J , Rao, Sunil V. , Shah, Binita , Aronow, Herbert D. , Banerjee, Subhash , Justino, Henri , Li, Jun , Morray, Brian H. , Parikh, Sahil A. , Reilly, John P. , Secemsky, Eric A. , Grines, Cindy L. , Baker, David, Berry, Charles, Cavalcante, Rafael , Diaz, Pedro, Kohler, Toni, Lowe, Sarah, Mueller, Megan, Patarca, Roberto , Stokes, Jerry, West, Nick E.J.

Mayo Clinic

Catheterization and Cardiovascular Interventions | August 16, 2021 | Volume: 98 | Issue: 5 | Pages: 904-913

10.1002/ccd.29898 | PMID 34398509 Get It

AbstractThe Society for Cardiovascular Angiography and Interventions (SCAI) Think Tank is a collaborative venture that brings together interventional cardiologists, administrative partners, and select members of the cardiovascular industry community annually for high‐level field‐wide discussions. The 2021 Think Tank was organized into four parallel sessions reflective of the field of interventional cardiology: (a) coronary intervention, (b) endovascular medicine, (c) structural heart disease, and (d) congenital heart disease. Each session was moderated by a senior content expert and co‐moderated by a member of SCAI's Emerging Leader Mentorship program. This document presents the proceedings to the wider cardiovascular community in order to enhance participation in this discussion, create additional dialog from a broader base, and thereby aid SCAI, the industry community and external stakeholders in developing specific action items to move these areas forward.
Pulmonary dose tolerance in hemithorax radiotherapy for Ewing sarcoma of the chest wall: Are we overestimating the risk of radiation pneumonitis?
Parekh, Akash D. , Indelicato, Daniel J. , Hoppe, Bradford S. , Vega, Raymond B. Mailhot , Rotondo, Ronny L. , Bradley, Julie A. , Hoppe, Bradford S , Parekh, Akash , Indelicato, Daniel J , Mailhot Vega, Raymond B

Mayo Clinic

Pediatric Blood & Cancer | August 16, 2021 | Volume: 68 | Issue: 11 | Pages: No page available

10.1002/pbc.29287 | PMID 34398486 Get It

AbstractBackgroundChildren with chest wall Ewing sarcoma with malignant pulmonary effusion or pleural stranding require hemithorax radiation, often with plans that exceed lung constraints. We investigated disease control and pneumonitis in children requiring hemithorax radiation.ProcedureEleven children (median age 13 years) received hemithorax radiotherapy. Symptomatic radiation pneumonitis was considered National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) grade 1+ with respiratory symptoms. Mean lung dose (MLD), volume of lung exposed to a dose ≥5 Gy (V5), ≥20 Gy (V20), and ≥35 Gy (V35) were recorded. Adult and pediatric lung constraints were obtained from Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC) guidelines and Children's Oncology Group (COG) protocols, respectively.ResultsMedian hemithorax dose was 15 Gy (1.5 Gy/fraction). Median total dose was 51 Gy (1.8 Gy/fraction). Most plans delivered both protons and photons. The ipsilateral MLD, V5, and V20 were 27.2 Gy, 100%, and 48.3%; the bilateral MLD, V20, and V35 were 14.1 Gy, 22.8%, and 14.3%, respectively. One hundred percent, 36%, and 91% of treatments exceeded recommended adult ipsilateral lung constraints of V5 <65%, V20 <52%, and MLD of 22 Gy; 64%, 45%, and 82% exceeded COG bilateral lung constraints of V20 <20%, MLD <15 Gy, and MLD <12 Gy, respectively; 82% of treatments exceeded the COG ipsilateral lung constraint of V20 <30%. At a median 36 months (range 12–129), the symptomatic radiation pneumonitis incidence was 0%. Two patients progressed with nonpulmonary metastatic disease and died at a median 12 months following radiotherapy.ConclusionsExisting guidelines may overestimate pneumonitis risk, even among young children receiving multiagent chemotherapy. For children with chest wall Ewing sarcoma and other thoracic malignancies, more data are needed to refine pediatric dose–effect models for pulmonary toxicity.
Association Between Transtibial Meniscus Root Repair and Rate of Meniscal Healing and Extrusion on Postoperative Magnetic Resonance Imaging: A Prospective Multicenter Study
Krych, Aaron J. , Nauert, Richard F. , Song, Bryant M. , Cook, Corey S., Johnson, Adam C. , Smith, Patrick A. , Krych, Aaron J , Stuart, Michael J.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | August 16, 2021 | Volume: 9 | Issue: 8 | Pages: No page available

10.1177/23259671211023774 | PMID 34423058 Get It

Background: Prospective studies evaluating second-look imaging of meniscus root repair using a transtibial pull-out technique are limited; therefore, optimal surgical indications and the technique for meniscus root repair remain uncertain. Hypothesis: It was hypothesized that there would be a high rate of healing, improvement in meniscal extrusion, and prevention of articular cartilage degeneration and subchondral bone abnormalities after meniscus root repair. Study Design: Case series; Level of evidence, 4. Methods: Consecutive patients undergoing transtibial root repair were prospectively enrolled at 2 orthopaedic centers between March 2017 and January 2019. Pre- and postoperative magnetic resonance imaging (MRI) scans were reviewed by a musculoskeletal radiologist in a blinded fashion for meniscal healing, quantification of extrusion, articular cartilage grade, subchondral bone changes, and coronary/meniscotibial ligament abnormalities. Given persistent extrusion observed on postoperative MRI scans, an additional 10 patients gave consent and were enrolled for immediate (before weightbearing) postoperative MRI scans. Results: A total of 45 patients (16 male, 29 female; mean ± standard deviation age, 42.3 ± 12.9 years; body mass index, 31.6) were prospectively enrolled in the study; there were 47 meniscus root repairs: 29 medial and 18 lateral (2 with both). Postoperative MRI was obtained at an average of 6.3 months (range, 5.1-8 months); 98% of meniscal repairs had evidence of healing. Mean extrusion increased significantly, from 1.9 ± 1.5 mm preoperatively to 2.6 ± 1.4 mm postoperatively ( P = .03). There was no significant progression of chondromalacia grade, subchondral edema, insufficiency fracture, subchondral cysts, or subchondral collapse. In the additional 10-patient cohort, the mean preoperative extrusion (1.6 ± 1.2 mm) was not significantly different from that immediately postoperatively (2.0 ± 1.0 mm; P = .23). Conclusion: Prospective MRI analysis of transtibial meniscus root repair confirmed a high rate of meniscal healing and no observable progression of cartilage degeneration or subchondral bone abnormalities at the short-term follow-up. However, meniscal extrusion worsened in the first 6 months after surgery. Registration: NCT03037242 ( ClinicalTrials.gov identifier).
Epidemiology of paediatric pain-related visits to emergency departments in the USA: a cross-sectional study
Anderson, Jana L. , Silva, Lucas Oliveira J. e , Funni, Shealeigh A., Bellolio, Fernanda , Jeffery, Molly M. , Oliveira J E Silva, Lucas , Jeffery, Molly Moore , Bellolio, M Fernanda

Mayo Clinic

BMJ Open | August 16, 2021 | Volume: 11 | Issue: 8 | Pages: e046497

10.1136/bmjopen-2020-046497 | PMID 34400448 Get It

Objective To describe the epidemiology of paediatric pain-related visits to emergency departments (EDs) across the USA. Design Cross-sectional study. Setting A representative sample of US ED visits using data from the National Hospital Ambulatory Medical Care Survey (NHAMCS). Participants Paediatric (age ≤18 years) ED visits in the 2017 NHAMCS data set. Data analysis Each visit was coded as pain-related or non-pain-related using the ‘reason for visit’ variable. Weighted proportions were calculated with 95% CIs. Logistic regression was used to compare odds of pain-related visits. Outcome measures Prevalence of pain-related visits among paediatric ED visits. Results There were an estimated 35 million paediatric ED visits in the USA in 2017, 55.6% (CI 53.3% to 57.8%) were pain related, which equates to 19.7 million annual visits. The prevalence of pain-related visits reached more than 50% of visits at age 6–7 and plateaued at relatively high proportions. Children of races other than white or black had lower odds of having a pain-related visit (OR 0.48, CI 0.29 to 0.81) than white children, as did children who were black, though the difference was not statistically significant (OR 0.88, CI 0.73 to 1.06). Relative to children covered by private insurance, children with Medicaid or CHIP (Children’s Health Insurance Program) coverage had lower odds of a pain-related visit (OR 0.75, CI 0.60 to 0.93). Injuries represented 46.5% (CI 42.0% to 51.0%) of pain-related visits. Pain scores were reported in less than 50% of pain-related visits. Conclusion Pain is the reason for visit in 55.6% of paediatric ED visits across the USA. The prevalence of pain-related visits peak before adolescence and it continues relatively high until the age 18. Injury, racial disparities in pain and poor pain score reporting should remain major topics of study in the paediatric population.
Intrarenal modulation of NF-κB activity attenuates cardiac injury in a swine model of CKD: a renal-cardio axis
Chade, Alejandro , Engel, Jason , Hall, Michael E. , Eirin, Alfonso , Bidwell, Gene L. , Chade, Alejandro R , Eirin, Alfonso

Mayo Clinic

American Journal of Physiology-Renal Physiology | August 16, 2021 | Volume: 321 | Issue: 4 | Pages: F411-F423

10.1152/ajprenal.00158.2021 | PMID 34396789 Get It

Chronic kidney disease (CKD) is a progressive disorder with high cardiovascular morbidity and mortality. This work supports the role of inflammatory cytokines of renal origin in renal-cardio pathophysiology in CKD and that the heart may be a target. Furthermore, it supports the feasibility of a new strategy in a translational fashion, using targeted inhibition of renal NF-κB signaling to offset the development of cardiac injury in CKD.